Article info
PDFResearch ethics
Paper
A randomised controlled trial of ribavirin in Crimean Congo haemorrhagic fever: ethical considerations
- Correspondence to Professor Berna Arda, Department of Medical Ethics, Faculty of Medicine, Ankara University, Ankara, Turkey; arda{at}medicine.ankara.edu.tr
Citation
A randomised controlled trial of ribavirin in Crimean Congo haemorrhagic fever: ethical considerations
Publication history
- Received July 8, 2011
- Revised August 12, 2011
- Accepted September 10, 2011
- First published October 12, 2011.
Online issue publication
January 20, 2012
Article Versions
- Previous version (12 October 2011).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Diagnostic tests for Crimean - Congo haemorrhagic fever: a widespread tickborne disease
- Crimean - Congo haemorrhagic fever presenting with acute compartment syndrome of the extremities (think beyond normal infections)
- Severe Crimean – Congo haemorrhagic fever presented with massive retroperitoneal haemorrhage that recovered without antiviral treatment
- Viral haemorrhagic fever in children
- Ribavirin restores IFNα responsiveness in HCV - infected livers by epigenetic remodelling at interferon stimulated genes
- Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria
- Cost - effectiveness analysis of sofosbuvir - based regimens for chronic hepatitis C
- Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C
- Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment - naïve patients infected with HCV genotype 1
- Cost effectiveness of peginterferon α -2b plus ribavirin versus interferon α -2b plus ribavirin for initial treatment of chronic hepatitis C